Welcome to our dedicated page for Cryo-Cell Intl news (Ticker: CCEL), a resource for investors and traders seeking the latest updates and insights on Cryo-Cell Intl stock.
Cryo-Cell International, Inc. (CCEL) is a NYSE American–listed company focused on cellular processing, cryogenic storage, and cord blood banking. The company describes itself as the world’s first private cord blood bank to separate and store stem cells, with operations that span private cord blood and cord tissue banking, a public cord blood banking program in partnership with Duke University, and technology and biostorage offerings such as PrepaCyte-CB and ExtraVault.
This news page aggregates company-issued updates and regulatory disclosures that affect Cryo-Cell’s business and capital structure. Readers can follow periodic financial results, where the company breaks out revenue from processing and storage fees, public banking activities, and product revenue. Dividend-related announcements are also a recurring theme, including the initiation of regular quarterly cash dividends, changes in dividend levels, and decisions not to declare dividends in certain quarters, often linked to profitability, capital requirements, and strategic priorities.
In addition to earnings and dividend news, Cryo-Cell’s releases highlight developments tied to its license agreement with Duke University, research and development spending related to clinical studies and manufacturing capabilities, and the launch and positioning of ExtraVault for biostorage and distribution services. Disclosures about strategic reviews, such as the pause of initiatives relating to a possible sale or merger of the company, provide further context on corporate strategy.
Investors and observers who want to monitor how Cryo-Cell’s cord blood banking operations, cellular therapy ambitions, and biostorage services evolve over time can use this page to review a chronological record of earnings releases, dividend decisions, strategic updates, and other material announcements.
Cryo-Cell International (NYSE:CCEL) reported fiscal third quarter results for the period ended August 31, 2025. Consolidated revenue was $7.83 million, down slightly from $8.07 million a year earlier. The company reported net income $749,000, or $0.09 per share, versus $1.05 million, or $0.13 per share, in the prior-year quarter.
Cryo-Cell reiterated operational credentials: FDA registration, cGMP/cGTP compliance, AABB and FACT accreditations, exclusive rights to PrepaCyte-CB processing, and more than 500,000 private clients across 87 countries.
Cryo-Cell International (NYSE American:CCEL), the world's first private cord blood bank, announced the suspension of its quarterly cash dividend for Q3 2025 due to lower-than-expected profitability. The company, which has stored stem cells for over 500,000 parents from 87 countries, maintains partnerships with Duke University and operates cord blood donation sites at prominent hospitals.
Founded in 1989, Cryo-Cell has achieved significant milestones including FDA registration, cGMP/cGTP compliance, and FACT accreditation. The company has expanded its services through initiatives like ExtraVault for biostorage solutions and holds exclusive rights to PrepaCyte-CB technology. Future dividend declarations will depend on financial performance, capital requirements, and strategic priorities.
Cryo-Cell International (NYSE American:CCEL), the world's first private cord blood bank, reported its fiscal Q2 2025 financial results. The company recorded revenue of $7.9 million, a slight 1% decrease from $8.0 million in Q2 2024. Net income decreased to $356,000 ($0.04 per share) from $656,000 ($0.08 per share) year-over-year.
The company's revenue breakdown included $7.87 million in processing and storage fees, $43,000 in public banking revenue, and $14,000 in product revenue. Cryo-Cell maintains a significant presence in the cord blood banking industry, serving over 500,000 parents from 87 countries and operating a public banking program in partnership with Duke University that has facilitated more than 700 transplants.
Cryo-Cell International (CCEL), the pioneering private cord blood bank, has announced a reduced quarterly cash dividend of $0.15 per share of common stock. The dividend will be paid on May 30, 2025, to shareholders of record as of May 21, 2025. The company cited the current economic environment and other capital allocation alternatives as reasons for the dividend reduction. The Board of Directors will continue to evaluate the dividend policy, with no guarantee of future dividend payments.
[ "Maintaining dividend payments despite economic challenges", "Clear commitment to returning value to shareholders" ]Cryo-Cell International (NYSE: CCEL), the world's first private cord blood bank, has reported its fiscal Q1 2025 financial results. The company's revenue increased to $7.97 million from $7.85 million in Q1 2024, primarily consisting of $7.87 million in processing and storage fees.
Net income decreased to $283,000 ($0.03 per share) compared to $556,000 ($0.07 per share) in the same period last year. The company serves over 500,000 parents from 87 countries and operates a public banking program with Duke University that has provided cord blood for more than 600 transplantations.
Cryo-Cell International (CCEL) reported its fiscal year 2024 financial results, showing consolidated revenues of $32.0 million, up from $31.3 million in 2023. The company achieved a net income of $402,000 ($0.05 per share) in 2024, compared to a net loss of $9.5 million in 2023.
The revenue breakdown included $31.6 million in processing and storage fees, $68,000 in product revenue, and $367,000 in public banking revenue. The company faced a $2.4 million income tax expense, with $1.3 million attributed to Florida's revenue apportionment methodology change. Realized and unrealized gains on marketable securities were $1.1 million in 2024, up from $51,000 in 2023.
Cryo-Cell International (NYSE American: CCEL), the world's first private cord blood bank, has announced two significant developments. First, the company's Board of Directors has approved a quarterly cash dividend of $0.25 per share of common stock, payable on February 28, 2025, to shareholders of record as of February 14, 2025. Second, the company has paused its strategic initiatives related to potential sale or merger activities.
The Board will continue to evaluate the dividend policy regularly, though they note there is no guarantee of future dividend payments. Cryo-Cell, which pioneered stem cell separation and storage in 1992, maintains its position as a leader in cord blood banking.
Cryo-Cell International (NYSE: CCEL), the world's first private cord blood bank, has announced the initiation of a regular quarterly cash dividend of $0.25 per share. The dividend will be paid on November 29, 2024, to shareholders of record as of November 15, 2024. The Board of Directors will evaluate the dividend policy regularly, considering factors such as earnings, cash flows, and capital requirements. The company's Chairman and Co-CEO David Portnoy emphasized this as a significant step in delivering shareholder value while continuing to evaluate strategic alternatives.
Cryo-Cell International, Inc. (NYSE: CCEL), the world's first private cord blood bank, reported its fiscal third quarter 2024 financial results. Highlights include:
- Revenue increased to $8.07 million, up from $7.87 million in Q3 2023
- Net income rose to $1.05 million ($0.13 per share), compared to $681,000 ($0.08 per share) in Q3 2023
- Gains on marketable securities were $522,000, up from $93,000 in Q3 2023
The company is exploring strategic alternatives to maximize shareholder value and considering instituting a regular quarterly dividend. Cryo-Cell's proposed spinoff of Celle Corp. is currently on hold due to a Demand for Arbitration filed with Duke University. The company continues to expand its services, including the launch of ExtraVault for biostorage and distribution solutions.
Cryo-Cell International, Inc. (NYSE American: CCEL), the world's first private cord blood bank, reported its fiscal second quarter 2024 financial results. Key highlights include:
- Revenue increased 3% to $8.0 million, compared to $7.8 million in Q2 2023
- Net income rose to $656,000 ($0.08 per share), up from $221,000 ($0.03 per share) in Q2 2023
- Cost of sales decreased by 6%
- Selling, general and administrative expenses decreased by less than 1%
- R&D expenses were $241,000, down from $305,000 in Q2 2023
The company's improved performance was driven by increased processing and storage fee revenue, which offset declines in public banking revenue.
FAQ
What is the current stock price of Cryo-Cell Intl (CCEL)?
What is the market cap of Cryo-Cell Intl (CCEL)?
